Ontology highlight
ABSTRACT:
SUBMITTER: Park KS
PROVIDER: S-EPMC4071378 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Park Kang-Seo KS Raffeld Mark M Moon Yong Wha YW Xi Liqiang L Bianco Caterina C Pham Trung T Lee Liam C LC Mitsudomi Tetsuya T Yatabe Yasushi Y Okamoto Isamu I Subramaniam Deepa D Mok Tony T Rosell Rafael R Luo Ji J Salomon David S DS Wang Yisong Y Giaccone Giuseppe G
The Journal of clinical investigation 20140609 7
The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. Unfortunately, a subset of patients with EGFR mutations are refractory to EGFR-TKIs. Resistance to EGFR inhibitors reportedly involves SRC activation and induction of epithelial-to-mesenchymal transition (EMT). Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein f ...[more]